Archives — April 2017 back to current month (10)

Good Epilepsy Data from Zynerba Pharmaceuticals Would Set Stage for Pivotal Trials (04/26/2017)

Maxim Group noted that data from Zynerba's Phase 2 proof of concept trial will be released in the third quarter; positive data would set the stage for Phase 3 trials.

more>

VistaGen's Fast-Acting Antidepressant Targets Multibillion-Dollar Market (04/26/2017)

Maxim Group recently initiated coverage of VistaGen Therapeutics, citing its progress on development of a fast-acting therapy to treat major depressive disorders.

more>

Trial Results Set Up DURECT Corp. for 'Exciting Year' (04/26/2017)

Positive results in a Phase 1b trial of DURECT Corp.'s candidate for the treatment of nonalcoholic steatohepatitis (NASH), which were presented at the 2017 International Liver Congress, prompted comments from a pair of analysts.

more>

2017 Small-Cap Biotech Watchlist Update: Holding Steady in a Volatile Market (04/19/2017)

The Small-Cap Biotech Watchlist, composed of 20 companies targeting a range of indications including blood cancers and solid tumors, irritable bowel disease and orphan diseases, has posted a modest gain since the first of the year.

more>

String of Positive Trial Results Boosts RepliCel's Profile (04/12/2017)

Positive results from RepliCel's Phase 1 trial for the treatment of aging and sun-damaged skin follow the release in the past few weeks of positive data from trials for chronic tendon problems and for hair loss.

more>

Five Companies with Favorable Risk/Reward Profiles from the AlphaNorth Capital Conference (04/12/2017)

The 4th annual AlphaNorth Capital Conference brought together over 40 emerging growth companies with top investors. In this interview with Streetwise Reports, Steve Palmer, founder and president of AlphaNorth Asset Management and a co-organizer of the conference, discusses a diverse group of companies that were selected to attend the conference, including three biotech companies.

more>

RXi Pharmaceuticals Receives Japanese Patent for RNAi Platform (04/12/2017)

With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform.

more>

Four Biotech Mid-Caps Fund Manager Eden Rahim Believes Have Favorable Catalysts (04/05/2017)

Biotech may be the last great bastion of stock picking, posits Eden Rahim, who manages the Toronto-based Next Edge Bio-Tech Plus Fund. The fund is up 40% in the last 12 months. In this interview with The Life Sciences Report, Rahim provides his view of the sector and profiles four companies he believes may have great upside.

more>

VistaGen Therapeutics Advances New-Generation Antidepressant Approved by European Patent Office (04/05/2017)

In a milestone for South San Francisco-based VistaGen Therapeutics, the European Patent Office (EPO) has issued a Notice of Intention to grant the company patents for its antidepressant prodrug, AV-101.

more>

Cash-Rich Zynerba's Synthetic Cannabinoid Product Line Ready to Rumble (04/05/2017)

Zynerba Pharmaceuticals specializes in developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Devon, Pennsylvania-based company's Q4/16 financial results disclose a substantial cash kitty of ~$78M available to fund its pipeline of medical marijuana products, ZYN001 and ZYN002.

more>

More Archives

2017Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

Notable Quotes

"We are initiating coverage on RVX with a Buy rating."
– David Kideckel, Beacon Securities Ltd.
"RXII's sd-rxRNA can augment already amazing results in immunotherapy."
– John Vandermosten, Zacks Small-Cap Research